New insights into atypical parkinsonism

Current Opinion in Neurology

Volumn 24, Issue 4, 2011, Pages 331-338

  Wenning, Gregor K ^a   Krismer, Florian ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

corticobasal degeneration; dementia with Lewy bodies; multiple system atrophy; progressive nuclear palsy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YL)ETHENYL] 6 [2 (FLUORO)ETHOXY]BENZOXAZOLE C 11; 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE I 123; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; DAVUNETIDE; IMMUNOGLOBULIN; LITHIUM; RASAGILINE; RIFAMPICIN; SYNUCLEIN; TAU PROTEIN; THREO 3,4 DIHYDROXYPHENYLSERINE; TRACER; UNCLASSIFIED DRUG; VALPROIC ACID;

ATYPICAL PARKINSONIAN DISORDER; CORTICOBASAL DEGENERATION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOGENESIS; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 79960842171     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283480569     Document Type: Review

References (96)

1. Wenning GK, Tolosa E, Litvan I. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011 (in press). Review of historical milestones and future perspectives in atypical parkinsonism.
2. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8:1172-1178.
3. Wenning GK, Stefanova N, Jellinger KA, et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008; 64:239-246.
4. Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010; 30:6236-6246.
5. Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007; 171:1291-1303. (Pubitemid 47582902)
6. Hasegawa T, Baba T, Kobayashi M, et al. Role of TPPP/p25 on alphasynuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 2010; 57:857-866.
7. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33:317-325.
8. Stefanova N, Hainzer M, Stemberger S, et al. Striatal transplantation for multiple system atrophy-are grafts affected by alpha-synucleinopathy? Exp Neurol 2009; 219:368-371.
9. Hirohata M, Ono K, Morinaga A, et al. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro alpha-synuclein fibril formation. Neurosci Lett 2011; 491:48-52.
10. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009; 65:610-614.
11. Al-Chalabi A, Durr A, Wood NW, et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009; 4:e7114.
12. Ross OA, Vilarino-Guell C, Wszolek ZK, et al. Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol 2010; 67:414-415.
13. Yun JY, Lee WW, Lee JY, et al. SNCA variants and multiple system atrophy. Ann Neurol 2010; 67:554-555.
14. Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. ArchNeurol 2007; 64:545-551. (Pubitemid 46588344)
15. Wullner U, Schmitt I, Kammal M, et al. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2009; 80:449-450.
16. Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25:2604-2612.
17. Colosimo C,Morgante L, Antonini A, et al. Nonmotor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010; 257:5-14.
18. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670-676.
19. Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133 (Pt 8):2382-2393.
20. Moreno-Lopez C, Santamaria J, Salamero M, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011; 68:223-230.
21. Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75:494-499.
22. Cochen De Cock V, Debs R, Oudiette D, et al. The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. Brain 2011; 134 (Pt 3):856-862.
23. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077-1081.
24. Lee JY, Yun JY, Shin CW, et al. Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. J Neurol 2010; 257:2065-2070.
25. Minnerop M, Luders E, Specht K, et al. Callosal tissue loss in multiple system atrophy-a one-year follow-up study. Mov Disord 2010; 25:2613-2620.
26. Tha KK, Terae S, Yabe I, et al. Microstructural white matter abnormalities of multiple system atrophy: in vivo topographic illustration by using diffusiontensor MR imaging. Radiology 2010; 255:563-569.
27. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9:149-158.
28. Goebel G, Seppi K, Donnemiller E, et al. A novel computer-assisted image analysis of [(123)I]beta-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. Eur J Nucl Med Mol Imaging 2011; 38:702-710.
29. Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010; 9:1070-1077.
30. Payoux P, Brefel-Courbon C, Ory-Magne F, et al. Motor activation in multiple system atrophy and Parkinson disease: a PET study. Neurology 2010; 75:1174-1180.
31. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53:1020-1025. (Pubitemid 29442118)
32. Nagayama H, Ueda M, Yamazaki M, et al. Abnormal cardiac [(123)I]-metaiodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010; 25:1744-1747.
33. Orimo S, Kanazawa T, Nakamura A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 2007; 113:81-86. (Pubitemid 44782932)
34. Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5- yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010; 133 (Pt 6):1772-1778.
35. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66:742-750.
36. Bloch F, Pichon B, Bonnet AM, et al. Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol 2010; 257:1986-1991.
37. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008; 18 (Suppl 1):25-29. (Pubitemid 351667201)
38. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008; 18 (Suppl 1):19-24. (Pubitemid 351667198)
39. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiplesystem-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25:97-107.
40. Park HJ, Bang G, Lee BR, et al. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy-parkinsonism. Cell Transplant 2010 [Epub ahead of print].
41. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83:723-730. (Pubitemid 351556019)
42. Kollensperger M, Krismer F, Pallua A, et al. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord 2011; 26:507-515.
43. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22:1689-1707; quiz 837. (Pubitemid 47597592)
44. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872. (Pubitemid 43970103)
45. Totterdell S, Meredith GE. Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience 2005; 135:907-913. (Pubitemid 41407753)
46. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120:131-143.
47. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300:636-640. (Pubitemid 36520587)
48. Clinton LK, Blurton-JonesM, Myczek K, et al. Synergistic interactions between a beta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30:7281-7289.
49. Meeus B, Nuytemans K, Crosiers D, et al. Comprehensive genetic and mutation analysis of familial dementia with Lewy bodies linked to 2q35-q36. J Alzheimers Dis 2010; 20:197-205.
50. Nervi A, Reitz C, Tang MX, et al. Familial aggregation of dementia with Lewy bodies. Arch Neurol 2011; 68:90-93.
51. Fujishiro H, Iseki E, Higashi S, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010; 486:19-23.
52. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010; 133 (Pt 2):540-556.
53. Kantarci K, Avula R, Senjem ML, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 2010; 74:1814-1821.
54. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74:885-892.
55. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 2010 [Epub ahead of print].
56. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebocontrolled, multicentre trial. Lancet Neurol 2009; 8:613-618.
57. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977.
58. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8:270-279.
59. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128 (Pt 6): 1247-1258. (Pubitemid 40826179)
60. Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22:2235-2241.
61. Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133 (Pt 7):2045-2057.
62. Whitwell JL, Jack CR Jr, Boeve BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75:1879-1887.
63. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66:41-48. (Pubitemid 43739589)
64. Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133 (Pt 6): 1578-1590.
65. Vidal JS, Vidailhet M, Derkinderen P, et al. Familial aggregation in atypical Parkinson's disease: a case control study in multiple system atrophy and progressive supranuclear palsy. J Neurol 2010; 257:1388-1393.
66. Pittman AM, Myers AJ, Duckworth J, et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet 2004; 13:1267-1274. (Pubitemid 38877880)
67. Melquist S, Craig DW, Huentelman MJ, et al. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500 288 single-nucleotide polymorphisms. Am J Hum Genet 2007; 80:769-778. (Pubitemid 46564413)
68. Rojo A, Pernaute RS, Fontan A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999; 122 (Pt 7):1233-1245. (Pubitemid 29324845)
69. Rohrer JD, Paviour D, Vandrovcova J, et al. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener Dis 2011; 8:149-152.
70. Chiu WZ, Kaat LD, Seelaar H, et al. Survival in progressive supranuclear palsy and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2010; 81:441-445.
71. O'Sullivan SS, Djamshidian A, Ahmed Z, et al. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord 2010; 25:638-642.
72. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1-9. (Pubitemid 26243849)
73. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010; 25:357-362.
74. Stamelou M, Knake S, Oertel WH, Hoglinger GU. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011; 258:549-558.
75. Colosimo C, Fabbrini G, Berardelli A. Progressive supranuclear palsy. In: Colosimo C, Riley DE, Wenning GK, editors. Handbook of atypical parkinsonism: Cambridge University Press; 2011.
76. Longoni G, Agosta F, Kostic VS, et al. MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord 2011; 26:247-255.
77. Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord 2010; 25:2444-2449.
78. Agosta F, Kostic VS, Galantucci S, et al. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. Eur J Neurosci 2010; 32:640-647.
79. Schofield EC, Hodges JR, Macdonald V, et al. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord 2011; 26:256-263.
80. Knake S, Belke M, Menzler K, et al. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Mov Disord 2010; 25:1232-1238.
81. Gilman S, Koeppe RA,NanB, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010; 74:1416-1423.
82. Aerts MB, Esselink RA, Abdo WF, et al. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2011 [Epub ahead of print].
83. Borroni B, Gardoni F, Parnetti L, et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 2009; 30:34-40.
84. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007; 4:507-509. (Pubitemid 350248382)
85. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23:942-949.
86. Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009; 16:297-309.
87. Litvan I, Chism A, Litvan J, et al. H1/H1 genotype influences symptom severity in corticobasal syndrome. Mov Disord 2010; 25:752-754.
88. Vandrovcova J, Anaya F, Kay V, et al. Disentangling the role of the tau gene locus in sporadic tauopathies. Curr Alzheimer Res 2010; 7:726-734.
89. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61:935-946. (Pubitemid 35278715)
90. YokotaO, Davidson Y, Bigio EH, et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 2010; 120:55-66.
91. Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TAR-DNAbinding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67:555-564. (Pubitemid 351787082)
92. Aerts MB, Esselink RA, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord 2011; 26:169-173.
93. Borroni B, Premi E, Agosti C, et al. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. J Neurol Neurosurg Psychiatry 2011 [Epub ahead of print].
94. Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010; 133 (Pt 7):2058-2068.
95. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102:6990-6995. (Pubitemid 40675429)
96. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule- interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-153. (Pubitemid 351439178)